Business Wire

Cognito Therapeutics Announces Spectris™ Demonstrates Durable Effects on Activities of Daily Living in the OVERTURE II Study

- Continued active treatment in the OVERTURE II OLE study demonstrated durability and preservation of brain structure and volume via MRI measurements over 18 months - Spectris™ treatment was well ...
Business Wire

Cognito Therapeutics Announces Non-invasive Neuromodulation Therapy Delays Alzheimer’s Disease Progression

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a pioneering neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, today announced new results from a ...
FierceBiotech

Cognito deepens analysis of neuromod device for Alzheimer’s with launch of biomarker substudy

As it plows ahead in its efforts to secure an FDA greenlight for its light- and sound-based neuromodulation device to treat Alzheimer’s disease, Cognito Therapeutics is taking an even closer look at ...
STAT

Cognito raises $35 million for Alzheimer’s treatment device, touts benefits compared to drugs

Just as a new wave of approved drugs for Alzheimer’s disease reaches patients, medical device company Cognito Therapeutics has raised a fresh $35 million to advance its alternative treatment for the ...